Curated News
By: NewsRamp Editorial Staff
December 29, 2024
Securities Class Action Lawsuit Filed Against Applied Therapeutics, Inc. by Kessler Topaz Meltzer & Check, LLP
Discuss on Reddit
LinkedIn
Telegram
GithubTLDR
- Investors can seek lead plaintiff status in a securities class action lawsuit against Applied Therapeutics, Inc., potentially gaining financial benefits.
- Investors who purchased Applied Therapeutics securities between January 3, 2024, and December 2, 2024, can file for lead plaintiff by February 18, 2025.
- Kessler Topaz Meltzer & Check, LLP helps investors seek justice against corporate misconduct, aiming to protect consumers, employees, and investors from fraud.
- Applied Therapeutics lawsuit highlights risks of drug trial protocol deviations, urging investors to take action before the lead plaintiff deadline on February 18, 2025.
Impact - Why it Matters
This news matters as it highlights potential misconduct by Applied Therapeutics, impacting investors who purchased securities during the specified period. Investors who suffered losses have the opportunity to seek compensation by becoming a lead plaintiff in the lawsuit. The outcome of this case could have significant implications for the pharmaceutical industry and regulatory oversight.
Summary
The law firm of Kessler Topaz Meltzer & Check, LLP has filed a securities class action lawsuit against Applied Therapeutics, Inc. on behalf of investors who purchased securities between January 3, 2024, and December 2, 2024. The lawsuit alleges that Applied Therapeutics did not adhere to trial protocol and good clinical practices for its drug candidate, govorestat, posing a risk of FDA rejection. The lead plaintiff deadline is February 18, 2025.
Source Statement
This curated news summary relied on this press release disributed by NewMediaWire. Read the source press release here, Securities Class Action Lawsuit Filed Against Applied Therapeutics, Inc. by Kessler Topaz Meltzer & Check, LLP
